ENGLEWOOD, Colo., March 23,
2022 /PRNewswire/ -- Ampio Pharmaceuticals,
Inc. (NYSE American: AMPE), a biopharmaceutical company
focused on the advancement of immunomodulatory therapies for
the treatment of pain resulting from osteoarthritis, announced that
the Company will be hosting its fourth quarter earnings and
business update call March 29 at
4:30pm EST.
Conference Call Details
Date/Time: March 29, 2022,
at 4:30 pm EST
Conferencing Link:
https://event.on24.com/wcc/r/3683372/9CD2C8B658E56541C487F44C34E897BB
Access Code: 66744
Canada dial-in
number (Toll Free):
|
1 833 950
0062
|
Canada dial-in
number (Local):
|
1 226 828
7575
|
US dial-in number
(Toll Free):
|
1 844 200
6205
|
US dial-in number
(Local):
|
1 646 904
5544
|
Access
code:
|
931547
|
*Participants will need to enter the participant access code
before being met by an operator
In order to submit questions, participants must have Internet
connectivity, as questions will only be addressed via the
webcast. The conference call line will be in listen-only
mode.
About Ampio
Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
for the treatment of pain resulting from osteoarthritis. Ampio's
lead drug, Ampion™, is backed by an extensive patent
portfolio with intellectual property protection extending through
2037 and may be eligible for 12-year FDA market exclusivity upon
approval as a novel biologic under the Biologics Price Competition
and Innovation Act (BPCIA).
Forward Looking
Statements
Ampio's statements in this press release and the webinar that
are not historical fact, and that relate to future plans or events,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as well
as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements, clinical trials and
decisions and changes in business conditions and similar events,
the ability to receive regulatory approval to conduct clinical
trials, that Ampion may be used to treat ARDS induced by COVID-19,
all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-hold-fourth-quarter-2021-earnings-and-business-update-call-301508715.html
SOURCE Ampio Pharmaceuticals, Inc.